9 reports of this reaction
1.5% of all ARFORMOTEROL TARTRATE reports
#16 most reported adverse reaction
PULMONARY OEDEMA is the #16 most commonly reported adverse reaction for ARFORMOTEROL TARTRATE, manufactured by Alembic Pharmaceuticals Inc.. There are 9 FDA adverse event reports linking ARFORMOTEROL TARTRATE to PULMONARY OEDEMA. This represents approximately 1.5% of all 613 adverse event reports for this drug.
ARFORMOTEROL TARTRATE has an overall safety score of 65 out of 100. Patients taking ARFORMOTEROL TARTRATE who experience pulmonary oedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY OEDEMA is a less commonly reported adverse event for ARFORMOTEROL TARTRATE, but still significant enough to appear in the safety profile.
In addition to pulmonary oedema, the following adverse reactions have been reported for ARFORMOTEROL TARTRATE:
The following drugs have also been linked to pulmonary oedema in FDA adverse event reports:
PULMONARY OEDEMA has been reported as an adverse event in 9 FDA reports for ARFORMOTEROL TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY OEDEMA accounts for approximately 1.5% of all adverse event reports for ARFORMOTEROL TARTRATE, making it a notable side effect.
If you experience pulmonary oedema while taking ARFORMOTEROL TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.